Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (251-260 of 483) with videos related to

Pageof 49
Sort By:
Cancer Research|November 3, 2012
CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motilityTamara Girbl, Elisabeth Hinterseer, Eva Melanie Grössinger, et al.
Journal of Clinical Medicine|June 5, 2020
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III TrialGabriel Rinnerthaler, Simon Peter Gampenrieder, Hubert Hackl, et al.
British Journal of Cancer|October 21, 2016
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patientsKatharina T Prochazka, Thomas Melchardt, Florian Posch, et al.
Wiener Klinische Wochenschrift|September 16, 2021
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMTTeresa Magnes, Sandro M Wagner, Thomas Melchardt, et al.
Phytochemistry|June 17, 2019
Lignans and sesquiterpene lactones from Hypochaeris radicata subsp. neapolitana (Asteraceae, Cichorieae)Oleksandr Shulha, Serhat Sezai Çiçek, Helle Wangensteen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapyMartin Filipits, Margaretha Rudas, Harald Heinzl, et al.
European Journal of Haematology|February 7, 2019
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIMFlorian Huemer, Thomas Melchardt, Bettina Jansko, et al.
Anticancer Research|January 1, 2015
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trialMagdalena Pircher, Brigitte Mlineritsch, Michael A Fridrik, et al.
Frontiers in Immunology|September 29, 2025
Impact of <i>Fusobacterium nucleatum</i> on immune cell interactions and gene expression in colorectal cancer: a retrospective cohort studyRonald Heregger, Florian Huemer, Richard Greil, et al.
BMC Cancer|January 11, 2022
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohortVerena Schlintl, Florian Huemer, Gabriel Rinnerthaler, et al.
Pageof 49

Showing results (251-260 of 483) with videos related to

Sort By:
Pageof 49
Cancer Research|November 3, 2012
CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motilityTamara Girbl, Elisabeth Hinterseer, Eva Melanie Grössinger, et al.
Journal of Clinical Medicine|June 5, 2020
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III TrialGabriel Rinnerthaler, Simon Peter Gampenrieder, Hubert Hackl, et al.
British Journal of Cancer|October 21, 2016
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patientsKatharina T Prochazka, Thomas Melchardt, Florian Posch, et al.
Wiener Klinische Wochenschrift|September 16, 2021
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMTTeresa Magnes, Sandro M Wagner, Thomas Melchardt, et al.
Phytochemistry|June 17, 2019
Lignans and sesquiterpene lactones from Hypochaeris radicata subsp. neapolitana (Asteraceae, Cichorieae)Oleksandr Shulha, Serhat Sezai Çiçek, Helle Wangensteen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapyMartin Filipits, Margaretha Rudas, Harald Heinzl, et al.
European Journal of Haematology|February 7, 2019
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIMFlorian Huemer, Thomas Melchardt, Bettina Jansko, et al.
Anticancer Research|January 1, 2015
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trialMagdalena Pircher, Brigitte Mlineritsch, Michael A Fridrik, et al.
Frontiers in Immunology|September 29, 2025
Impact of <i>Fusobacterium nucleatum</i> on immune cell interactions and gene expression in colorectal cancer: a retrospective cohort studyRonald Heregger, Florian Huemer, Richard Greil, et al.
BMC Cancer|January 11, 2022
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohortVerena Schlintl, Florian Huemer, Gabriel Rinnerthaler, et al.
Pageof 49